Want $1,188 in Passive Income? Invest $5,000 Into These 3 High-Yielding Stocks

The article highlights three high-yield equities—Conagra Brands at 9.88%, Campbell’s at 7.57%, and Pfizer at 6.37%—that together generate $1,188.52 of annual income on a $15,000 investment, for a blended yield of 7.92%. Pfizer guided FY2026 revenue to $59.5 billion-$62.5 billion and adjusted EPS to $2.80-$3.00, while Campbell’s cut FY26 EPS guidance to $2.15-$2.25 and Conagra narrowed FY26 EPS guidance to about $1.70. Overall tone is income-focused and defensive, emphasizing elevated yields versus a 10-year Treasury yield of 4.34%.

Analysis

The screen is really a bet on duration: investors are choosing to monetize equity cash yield while waiting for operational fixes that may take 4-8 quarters to show up. The immediate winners are not just the three issuers, but also lower-quality capital allocators elsewhere that will now face a higher hurdle rate for repurchases and dividend growth; anything yielding sub-3% with no growth will look increasingly like dead money if 10-year yields stay above 4%.

The more interesting second-order effect is competitive pressure in packaged foods and branded pharma. In staples, high payout ratios and sluggish volume trends mean these companies are effectively bidding for shelf space with cash returns rather than growth, which tends to force private-label share gains unless pricing power re-accelerates. In pharma, the dividend is acting as a valuation floor, but it also signals management has limited organic growth urgency; the real upside catalyst is pipeline/read-through or M&A, not the payout itself.

The contrarian risk is that the yields are high for a reason and the market may be underpricing secular erosion rather than cyclical softness. For CAG and CPB, the danger window is the next 2-3 earnings prints: if volumes keep deteriorating, the dividend becomes a governance question, not an attraction, because FCF coverage can look fine right up until it doesn't. For PFE, the key horizon is 12-24 months; a stable dividend is credible, but absent a visible growth inflection, any multiple rerating is capped by investor skepticism around post-patent cash replacement.

BLK and STT matter because they are the meta-beneficiaries of this income trade: higher rate volatility and a renewed hunt for yield should support asset-gatherers and custodians even if the underlying dividend names lag. The market may be missing that a persistent 4%+ risk-free rate compresses the universe of acceptable equity income, which can create relative winners in asset management even when defensive dividend stocks remain under pressure.

Key Decisions for Investors

• Long PFE vs short XLP basket for 3-6 months: own the cleanest balance-sheet-supported yield in the group while fading broad staples multiple risk; target 8-12% spread if rate-backed income remains in favor.
• Avoid outright longs in CAG and CPB ahead of the next 1-2 earnings prints; if seeking exposure, use call spreads only after confirmation that volumes stabilize, because dividend support does not prevent another 10-15% drawdown on guidance cuts.
• Long BLK and/or STT on any yield-driven market wobble over the next 1-2 quarters: if capital rotates into income products and rate volatility stays elevated, these names should compound AUM/fee leverage faster than the cash-yield stocks rerate.
• For PFE, sell cash-secured puts or run a delayed-entry long on weakness over the next 6-12 weeks; downside is cushioned by yield, but upside requires a catalyst, so patience improves entry versus chasing the stock.
• Pair trade: long BLK / short CAG for 3-6 months as a relative-value expression of the same rate environment; the former benefits from the hunt for yield, while the latter is exposed to margin compression and dividend skepticism.